by Claudia Campos
311healthbeat.blogspot.com
Wall Street Journal article "New Anemia Drug Restrictions Possible," by Anna Mattews and Marilyn Chase on www.wsj.com, said that anemia drugs Procrit, Epogen and Aranesp used by cancer patients are getting tighter safety writing labels by FDA. The article said that there is a connection between short survival, fast tumor growth and blood clots because the drugs increase the red blood cells in cancer patients and decrease tumor growth and blood clots.
These drugs are part of the chemotherapy treatment which are reducing the need for blood transfusions. Patients are said not to be in harms way if they stop taking the drugs but continuance on research and studies are being conducted and the FDA has a strong hold on the drugs safety labels.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment